The weather is cooling, but the health industry is heatings things up. OneMedSentinel is pleased to bring you another round of stories and interviews with some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: Tom Moore, CEO of Advaxis [ADXS] speaks confidently about his technology’s ability to ensure immunity from certain cancers. Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics”. Peter has over 30 years experience as a scientist, science…
Browsing: Uncategorized
OneMedSentinel continues coverage of some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: Rodman and Renshaw gears up for their 13th Annual Global Investment Conference. David Strupp discusses the firm and why it’s annual conference has become the world’s biggest and most anticipated next to JP Morgan’s. Wound Management [WNDM] President, Deborah Jenkins Hutchinson discusses the company’s plan to become cash flow positive and profitable within the next year. The outlook is promising with their recent distribution agreement in place for CellerateRX. Other interviews: Verisante Technologies [VRS] CEO,…
OneMedRadio interviewed Thomas Braun, CEO of Verisante Technologies [CVE:VRS], a medical device company committed to commercializing innovative systems for the early detection of cancer.
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
Frank Reynolds, President and CEO of InVivo Therapeutics describes the company’s strategy in bringing its unique spinal cord injury (SPI) products to market.
Novadaq Technologies (TSX:NDQ) President & CEO Arun Menawat, Ph.D was interviewed by OneMedRadio and discusses the roll out of his surgical imaging technology.
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.